目的 探討魚腥草滴眼液治療流行性角結(jié)膜炎的療效和安全性，并進(jìn)行藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)。方法 將200例流行性角結(jié)膜炎患者隨機(jī)分為治療組（150例）和對(duì)照組（50例），治療組給予魚腥草滴眼液，1滴/次，6次/d，對(duì)照組給予復(fù)方熊膽滴眼液，用法和用量同治療組。采用單盲、平行性對(duì)照研究，療程均為10 d。觀察2組療效及不良反應(yīng)，并運(yùn)用成本–效果分析法進(jìn)行藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)。結(jié)果 治療組和對(duì)照組臨床愈顯率分別為84%、66%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.01）；總有效率分別為98%、88%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。不良反應(yīng)發(fā)生率差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05），但治療組成本–效果比低于對(duì)照組（P＜0.01）。結(jié)論 魚腥草滴眼液治療流行性角結(jié)膜炎療效較好，臨床應(yīng)用安全，經(jīng)濟(jì)學(xué)優(yōu)勢(shì)更加明顯。

Objective To evaluate the clinical efficacy and safety of Yuxingcao Gutta, an eye drop consisted of Houttuyniae Herba, in the treatment of epidemic keratoconjunctivitis and to evaluate its pharmacoeconomics. Methods The patients with epidemic keratoconjunctivitis (200 cases) were randomly divided into the treatment (150 cases) and control (50 cases) groups, which were administered with Yuxingcao Gutta and Compound Xiongdan Gutta which was an eye drop consisted of Ursi Fel, one drop once for six times daily, respectively. The course of treatment was 10 d, and the single-blind and parallel-controlled contrast studies were adopted. The clinical efficacy and safety of the two groups were observed and evaluated by the cost-effectiveness method of pharmacoeconomics. Results The markedly effective rate in the treatment and control groups were 84% and 66%, respectively, with the significant difference between the two groups (P < 0.01), and the efficacies in the treatment and control groups were 98% and 88%, respectively, with the significant difference between two groups (P < 0.05). There were no differences between the two groups on safety (P > 0.05), but the cost-effectiveness of the treatment group was lower than that of the control group (P < 0.01). Conclusion The clinical efficacy of Yuxingcao Gutta is better in the treatment of epidemic keratoconjunctivitis and the therapeutic effect is reliable and safe, and has more obvious economic advantages.